Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: M.D. Anderson Cancer Center
Cephalon
Information provided by: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00469209
  Purpose

Primary Objectives:

  1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma
  2. To evaluate the efficacy of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma
  3. To determine the effects of bortezomib on melphalan pharmacokinetics

Condition Intervention Phase
Myeloma
Drug: Trisenox (Arsenic Trioxide)
Drug: Velcade (Bortezomib)
Drug: Melphalan
Drug: Vitamin C (Ascorbic Acid)
Phase I
Phase II

Genetics Home Reference related topics: aceruloplasminemia hemophilia
MedlinePlus related topics: Arsenic Cancer Multiple Myeloma
Drug Information available for: Melphalan Arsenic trioxide Bortezomib Melphalan hydrochloride Sarcolysin Ascorbic acid
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title: Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment: 60
Study Start Date: June 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. a) Primary Refractory Disease (defined as failure to achieve even a partial response to induction therapy) b) Consolidation of a partial remission (defined as a decrease but continued presence of monoclonal protein on serum and urine immunofixation electrophoresis, and/or the presence of plasmacytosis on bone marrow aspirate and biopsy) c) Relapsing after prior therapy (disease relapsing after achieving a partial or complete response to prior conventional or high-dose therapy) .
  2. Age up to 75 years.
  3. Zubrod PS of <2.
  4. Left ventricular ejection fraction >40%. No uncontrolled arrhythmias or symptomatic cardiac disease.
  5. FEV1, FVC and DLCO >40%. No symptomatic pulmonary disease.
  6. Serum bilirubin <2 X upper limit of normal, SGPT <4 X upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No effusion or ascites >1L prior to drainage.
  7. HIV-negative.
  8. Negative Beta HCG test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization
  9. Patient or guardian able to sign informed consent
  10. Corrected QT interval less than 470 msec.

Exclusion Criteria:

  1. Corrected QT interval greater than 470 msec.
  2. Patients in complete remission (defined as the absence of monoclonal protein on serum and urine immunofixation electrophoresis, and the absence of plasmacytosis in bone marrow aspirate and biopsy).
  3. Patients with non-secretory myeloma.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00469209

Locations
United States, Texas
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Cephalon
Investigators
Principal Investigator: Muzaffar H. Qazilbash, MD U.T.M.D. Anderson Cancer Center
  More Information

Study ID Numbers: 2005-0893
Study First Received: May 3, 2007
Last Updated: September 7, 2007
ClinicalTrials.gov Identifier: NCT00469209  
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Multiple Myeloma
Melphalan
Trisenox
Arsenic Trioxide
Ascorbic Acid
Vitamin C
Velcade
Bortezomib

Study placed in the following topic categories:
Melphalan
Immunoproliferative Disorders
Blood Protein Disorders
Hematologic Diseases
Blood Coagulation Disorders
Bortezomib
Vascular Diseases
Arsenic trioxide
Paraproteinemias
Hemostatic Disorders
Multiple Myeloma
Hemorrhagic Disorders
Multiple myeloma
Lymphoproliferative Disorders
Ascorbic Acid
Neoplasms, Plasma Cell

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Antioxidants
Immunologic Factors
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Growth Substances
Physiological Effects of Drugs
Enzyme Inhibitors
Immunosuppressive Agents
Protective Agents
Pharmacologic Actions
Protease Inhibitors
Neoplasms
Therapeutic Uses
Vitamins
Myeloablative Agonists
Cardiovascular Diseases
Antineoplastic Agents, Alkylating
Micronutrients
Alkylating Agents

ClinicalTrials.gov processed this record on January 16, 2009